Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in Polymyalgia Rheumatica
NCT07670546Phase 3Active, not recruiting
- Sponsor
- R-Pharm
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
A Phase 3 trial of olokizumab in polymyalgia rheumatica (PMR), sponsored by R-Pharm. Started Jun 2025; status: active, not recruiting.
02
Drugs
olokizumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT07670546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670546.